First malaria vaccine in Africa: A potential new tool for child health and improved malaria control


Publication details

Number of pages: 4
Publication date: April 2018 (updated November 2019)
Languages: English
WHO reference number: WHO/CDS/GMP/2018.05.Rev 1



A first generation vaccine known as RTS,S/AS01 (RTS,S) acts against Plasmodium falciparum, the most deadly malaria parasite globally and the most prevalent in Africa. The vaccine is the first and only vaccine to reduce malaria cases in young children in Africa, the population most affected by the disease. Rigorous clinical testing in 7 African countries has shown its potential to boost malaria prevention and save lives.

The Malaria Vaccine Implementation Programme (MVIP) was established by WHO to coordinate and support the introduction of the vaccine in selected areas of Africa through country-led routine immunization. The Programme will evaluate the vaccine’s public health impact in the context of routine use and inform policy about its potential deployment on a broader scale.

Related links